A study by Canadian researchers shows that preventive oophorectomy reduces risk of ovarian, fallopian tube, or peritoneal cancer by 80% in women who have BRCA1 or BRCA2 mutations. Published in The Journal of Clinical Oncology, the report also documented a 77% reduction in all-cause mortality.
A study by Canadian researchers shows that preventive oophorectomy reduces risk of ovarian, fallopian tube, or peritoneal cancer by 80% in women who have BRCA1 or BRCA2 mutations. Published in The Journal of Clinical Oncology, the report also documented a 77% reduction in all-cause mortality.
An international registry was used to identify 5783 women with a BRCA1 or BRCA2 mutation, who then completed a baseline questionnaire and at least one follow-up questionnaire. The participants were observed until they were diagnosed with ovarian, fallopian, or peritoneal cancer, death, or date of most recent follow-up. The goal was to assess the impact of prophylactic oophorectomy on all-cause mortality and estimate 5-year survival associated with clinically detected ovarian, occult, and peritoneal cancers diagnosed in the cohort.
After average follow up of 5.6 years, a total 186 women developed ovarian (n=132), fallopian (n=22), or peritoneal (32) cancer, 68 of whom have died. Bilateral oophorectomy was associated with a hazard ratio (HR) for ovarian, fallopian, or peritoneal cancer of 0.20 (95% CI, 0.13 to 0.30; P< .001). The HR for all-cause mortality at age 70 years associated with oophorectomy was 0.23 (95% CI, 0.13 to 0.39; P< .001) for women who had no history of cancer at baseline.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.
Unlocking placenta accreta spectrum with single-cell gene targets
April 18th 2024Discover how cutting-edge single-cell RNA sequencing unveils molecular insights into placenta accreta spectrum disorders, potentially revolutionizing diagnostics and treatments for this life-threatening pregnancy complication.
Read More
Excessive gonadotropins in IVF: Effects on mosaicism and live birth
April 12th 2024A recent study revealed a correlation between high doses and prolonged duration of exogenous gonadotropin use during in vitro fertilization and increased embryonic mosaicism alongside diminished live birth rates, prompting reconsideration of dosage and duration protocols.
Read More
Dostarlimab shows significant survival benefits in endometrial cancer trial
March 21st 2024GlaxoSmithKline's phase 3 trial demonstrated promising overall and progression-free survival outcomes in patients with primary advanced or recurrent endometrial cancer, paving the way for potential FDA approval.
Read More